Biovica International AB (publ) Stock Nasdaq Stockholm
Equities
SE0008613731
Biotechnology & Medical Research
Sales 2025 * | 42M 3.96M | Sales 2026 * | 140M 13.21M | Capitalization | 231M 21.82M |
---|---|---|---|---|---|
Net income 2025 * | -70M -6.61M | Net income 2026 * | -41M -3.87M | EV / Sales 2025 * | 4.1 x |
Net cash position 2025 * | 59M 5.57M | Net cash position 2026 * | 38.67M 3.65M | EV / Sales 2026 * | 1.37 x |
P/E ratio 2025 * |
-3.93
x | P/E ratio 2026 * |
-6.66
x | Employees | - |
Yield 2025 * |
-
| Yield 2026 * |
-
| Free-Float | 92.54% |
Latest transcript on Biovica International AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 09-12-31 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 22-12-31 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 64 | 19-03-19 | |
Annika Berg
BRD | Director/Board Member | 61 | 19-12-31 |
Maria Holmlund
BRD | Director/Board Member | 68 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-42.89% | 7.8B | |
+6.77% | 3.53B | |
-1.35% | 2.24B | |
-27.06% | 1.84B | |
-21.23% | 1.66B | |
+9.31% | 951M | |
+29.42% | 811M | |
-12.66% | 670M | |
-26.12% | 533M |